ST.LOUIS (April 23, 2010)—Solutia Inc., the parent of Flexsys, said it is withdrawing from the primary accelerator business.
The company is to cease manufacture of these products at its Antwerp facility during the second half of this year. Solutia said it is working with all affected parties to ensure a smooth transition.
Flexsys' range of primary accelerators includes sulphenamides, mercaptos and thiazoles.
Solutia said this decision does not affect the Santoflex PPD manufacturing operations at Antwerp, including production of 4-ADPA, the key intermediate for Solutia's Santoflex(R) line of antidegradants.
Solutia said it made the decision because of fierce price competition notably from Asian suppliers.